Medtronic Plc(MDT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 23.13 | EPS (ttm) | 4.06 | Insider Own | 0.09% | Shs Outstand | 1.28B | Perf Week | -0.72% |
| Market Cap | 120.18B | Forward P/E | 14.69 | EPS next Y | 6.99% | Insider Trans | -5.67% | Shs Float | 1.28B | Perf Month | 4.97% |
| Enterprise Value | 140.13B | PEG | 1.9 | EPS next Q | 1.33 | Inst Own | 88.86% | Short Float | 10.88% | Perf Quarter | 7.32% |
| Income | 5.23B | P/S | 3.2 | EPS this Y | 8.09% | Inst Trans | -1.94% | Short Ratio | 8.5 | Perf Half Y | 14.71% |
| Sales | 37.54B | P/B | 2.39 | EPS next 5Y | 7.72% | ROA | 5.68% | Short Interest | 139.00M | Perf YTD | -2.2% |
| Book/sh | 39.24 | P/C | 13.63 | EPS past 3/5Y | 9.75% 6.95% | ROE | 10.66% | 52W High | -11.64% ($106.33) | Perf Year | -0.19% |
| Cash/sh | 6.89 | P/FCF | 19.6 | Sales past 3/5Y | 5.21% 3.84% | ROIC | 6.9% | 52W Low | 28.15% ($73.31) | Perf 3Y | 35.32% |
| Dividend Est. | $2.83 (3.01%) | EV/EBITDA | 13.45 | EPS Y/Y TTM | 12.28% | Gross Margin | 60.56% | Volatility(W/M) | 2.15% 2.47% | Perf 5Y | -23.31% |
| Dividend TTM | 2.86 | EV/Sales | 3.73 | Sales Y/Y TTM | 9.77% | Oper. Margin | 19.93% | ATR (14) | 2.25 | Perf 10Y | 15.8% |
| Dividend Ex-Date | 2026/9/25 | Quick Ratio | 1.54 | EPS Q/Q | 41.57% | Profit Margin | 13.93% | RSI (14) | 55.25 | Recom | 1.81 |
| Dividend Gr. 3/5Y | 1.45% 4.13% | Current Ratio | 2.07 | Sales Q/Q | 13.73% | SMA20 | 2.88% ($91.32) | Beta | 0.6 | Target Price | $103.82 |
| Payout | 76.2% | Debt/Eq | 0.56 | Earnings | 2026/9/1 | SMA50 | 2.67% ($91.51) | Rel Volume | 0.33 | Prev Close | $94.79 |
| Employees | 95000 | LT Debt/Eq | 0.51 | EPS/Sales Surpr. | 4.44% 2.2% | SMA200 | 6.54% ($88.18) | Avg Volume(3M) | 16.35M | Price | $93.95 |
| IPO | 1977/11/21 | Option/Short | Yes/Yes | Trades | 40964 | Volume | 5,454,327 | Change | -0.89% |
🩺 A global medical device conglomerate with an extensive portfolio spanning cardiovascular, neuroscience, surgical, and diabetes care. Founded in the United States in 1949 and headquartered in Ireland, it is a comprehensive medical device group holding a leading position in the global medical device market.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
Traded less than usual. That is 33% of its average volume.
MDT earns at a steady pace
Of every $100 in sales, $19.93 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +8.1% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $2,313. Peers typically go for $2,793. Compared with its own 4-year average, it is 39% cheaper now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -23.3%. The S&P 500 did +70% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 3.01% annually in dividends.
Tap to view numbers
Ownership is about average
Institutions hold 88.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #2 of 142 in the industry
Based on market cap of $120B.
FAQ
What kind of company is MDT?
MDT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of MDT?
The market cap of MDT is approximately $120.2B, ranking 130 within its sector.
Does MDT pay dividends?
MDT has a dividend yield of approximately 3.01%, with an annual dividend of $2.83.
What is the P/E ratio of MDT?
MDT has a P/E ratio of approximately 23.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MDT?
MDT has recorded a 52-week high of $106.33 and a low of $73.31.
